Neuphoria Therapeutics (NEUP) Research & Development (2023 - 2025)

Neuphoria Therapeutics (NEUP) has reported Research & Development for 3 consecutive years, with $697723.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Research & Development fell 59.83% year-over-year to $697723.0 in Q4 2025; TTM through Dec 2025 was $9.9 million, a 24.18% increase from a year earlier, with the FY2025 full-year figure at $9.0 million, down 4.38% from the prior year.
• Research & Development was $697723.0 for Q4 2025 at Neuphoria Therapeutics, down from $3.8 million in the prior quarter.
• Over five years, Research & Development peaked at $3.8 million in Q3 2025 and troughed at $697723.0 in Q4 2025.
• A 3-year average of $2.3 million and a median of $2.0 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 99.15% in 2025, down 59.83% in 2025.
• Over 3 years, Research & Development stood at $2.0 million in 2023, then dropped by 14.64% to $1.7 million in 2024, then plunged by 59.83% to $697723.0 in 2025.
• The last three Research & Development figures came in at $697723.0 (Q4 2025), $3.8 million (Q3 2025), and $3.8 million (Q2 2025), per Business Quant data.